FIELD Study: Fenofibrate in T2DM
The Lancet (2005)
Reduced diabetic retinopathy progression by 37% and peripheral revascularization by 38% in 9,795 T2DM patients.
How it works
Marek's Guided Optimization® Program combines advanced lab testing, a dedicated health coach and medical provider, and a personalized treatment plan, all built around your data.
Resources
The process
Start your assessment
Complete your 45-min intake assessment
Get your labs drawn
4,000 partnered lab locations nationwide
Review with your coach
Screen-by-screen lab review
Receive your protocol
Treatment delivered to your door
Why Marek
The only program pairing you with a dedicated health coach and medical provider, built on precision diagnostics, with no subscription required.
Resources
Meet our co-founder
Derek
Co-Founder · MPMD Podcast
"Over time, I found it incredibly difficult to get medical oversight for myself and my family that reflected the latest research, and that was preventative. That's why I started Marek Health."

What we test
Every client's lab panel is hand-selected from 1,000+ available biomarkers, built around their specific goals.
Panel categories
Resources
Treatments
700+ medical provider-prescribed therapies built from your labs. Browse by category or explore the full formulary.
Fenofibrate
Oral tablet (145mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
PPAR-alpha agonist for hypertriglyceridemia and mixed dyslipidemia. Reduces microvascular complications in T2DM (retinopathy 37% reduction in FIELD trial). Also has uricosuric effects. Preferred fibrate with statins (lower myopathy risk vs gemfibrozil).
TG reduction 30 to 50%
HDL-C increase 10 to 20%
Diabetic retinopathy reduction 37% (FIELD)
Uricosuric effect reduces gout risk
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Activates PPAR-alpha in hepatocytes and muscle, upregulating lipoprotein lipase and fatty acid oxidation genes. Increases triglyceride clearance, reduces VLDL production, raises HDL-C, and shifts LDL to large-buoyant particles.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
The Lancet (2005)
Reduced diabetic retinopathy progression by 37% and peripheral revascularization by 38% in 9,795 T2DM patients.
Safety profile
FAQ
PPAR-alpha agonist for hypertriglyceridemia and mixed dyslipidemia. Reduces microvascular complications in T2DM (retinopathy 37% reduction in FIELD trial). Also has uricosuric effects. Preferred fibrate with statins (lower myopathy risk vs gemfibrozil).
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.